--- canonical_name: CJC-1295 alternate_names: "CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF, CJC-1295 with DAC" canonical_topic: CJC-1295 for Health & Longevity short_topic_lc: cjc_1295 creation_date: 2026-0702-0226 creator_ai_fullname: Opus 4.8 --- # CJC-1295 for Health & Longevity
Evidence Review created on 07/02/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF, CJC-1295 with DAC ## Motivation CJC-1295 is a lab-made copy of a natural signaling molecule that tells the brain's master gland to release growth hormone. It was engineered so that a single injection keeps working for many days, rather than the few minutes the natural version lasts. People interested in staying healthy as they age are drawn to it because growth hormone and the downstream messenger it triggers tend to fall with age, and CJC-1295 raises both by prompting the body to make its own. The compound was first tested in humans around 2006 by the company that created it, and those early trials showed it reliably lifts growth hormone and its downstream messenger for over a week per dose. It never became an approved medicine, and today it circulates mostly through compounding pharmacies and the loosely regulated peptide market, often paired with a second peptide. This review examines what is actually known about CJC-1295: how it works, what the small human evidence base shows, its possible benefits, its risks, and the many open questions around long-term safety and product quality. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level expert resources that discuss CJC-1295 by name in the context of growth hormone optimization and longevity. * [AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field](https://peterattiamd.com/ama83/) - Peter Attia Attia dedicates a full case study to CJC-1295, walking through its growth hormone–stimulating mechanism, the limited human data, dosing uncertainty, and the lack of long-term safety information, and explains why he places it in a cautious risk-reward tier. * [Benefits & Risks of Peptide Therapeutics for Physical & Mental Health](https://www.hubermanlab.com/episode/benefits-risks-of-peptide-therapeutics-for-physical-mental-health) - Andrew Huberman This episode maps the landscape of growth hormone secretagogue peptides, contrasting CJC-1295 with sermorelin and tesamorelin and flagging its greater fluid-retention and safety concerns relative to alternatives. * [Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults](https://pubmed.ncbi.nlm.nih.gov/16352683/) - Teichman et al., 2006 The foundational human trial establishing the pharmacokinetics and pharmacodynamics of CJC-1295, showing dose-dependent, multi-day elevations in growth hormone and IGF-1 (insulin-like growth factor 1, the main downstream messenger through which growth hormone acts) in healthy adults. * [Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog](https://pubmed.ncbi.nlm.nih.gov/17018654/) - Ionescu & Frohman, 2006 A mechanistically important human study demonstrating that CJC-1295 raises baseline and average growth hormone while preserving the natural pulsing pattern, which is thought to matter for the hormone's physiological effects. * [Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions](https://pubmed.ncbi.nlm.nih.gov/26771670/) - Van Hout & Hearne, 2016 A qualitative study of how CJC-1295 is discussed and used in real-world online communities, offering rare insight into self-administration practices, dosing beliefs, and stacking behavior outside clinical settings. Note: Of the priority experts, only Peter Attia and Andrew Huberman have dedicated CJC-1295 coverage. No dedicated CJC-1295 content was found for Rhonda Patrick, Chris Kresser, or Life Extension Magazine; the remaining slots are filled with qualifying primary human research rather than marginally relevant commercial content. ## Grokipedia * [CJC-1295](https://grokipedia.com/page/CJC-1295) - Grokipedia A fact-checked reference entry covering CJC-1295's structure, its albumin-binding drug affinity complex, the extended half-life, the human pharmacokinetic data, and its regulatory standing, providing a concise technical overview of the compound. ## Examine No Examine article exists for CJC-1295. CJC-1295 is an injectable research peptide rather than a dietary supplement, and Examine.com does not typically cover compounds of this type. ## ConsumerLab No ConsumerLab article exists for CJC-1295. ConsumerLab.com reviews and tests dietary supplements and does not typically cover injectable research peptides such as CJC-1295. ## Systematic Reviews No systematic reviews or meta-analyses for CJC-1295 were found on PubMed as of 07/02/2026. ## Mechanism of Action CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural hypothalamic signal (a plain-language term for the brain's hormone-control center) that instructs the pituitary gland to make and release growth hormone (GH). It is built from the first 29 amino acids of natural GHRH — the shortest fragment that still activates the receptor — with four amino acid substitutions that resist breakdown by the enzyme DPP-4 (dipeptidyl peptidase-4, an enzyme that rapidly chops up many peptide hormones). The defining feature of CJC-1295 is its drug affinity complex (DAC), a chemical group that binds covalently and permanently to albumin, the most abundant protein in blood. By hitching a ride on albumin, the peptide escapes rapid kidney filtration and enzymatic destruction, which is why its half-life stretches to roughly 6–8 days instead of the few minutes of natural GHRH. By continuously stimulating the pituitary, CJC-1295 raises both baseline and average GH output, which in turn drives the liver to produce more IGF-1, the main downstream messenger through which GH exerts many of its growth and repair effects. Importantly, human data show that despite this continuous stimulation, the natural pulsing rhythm of GH release is preserved — the frequency and size of GH pulses are largely unchanged, while the low points between pulses rise substantially. A competing mechanistic consideration concerns whether "more GH/IGF-1 is beneficial." Proponents argue that restoring youthful GH/IGF-1 signaling supports lean mass, recovery, and tissue repair. Critics counter that chronically elevated IGF-1 is mechanistically linked in aging biology to accelerated growth signaling (via pathways such as mTOR, a central nutrient- and growth-sensing pathway) and potentially to cancer and reduced longevity, so the same mechanism that produces desired effects may carry theoretical long-term costs. As a pharmacological compound, CJC-1295's key properties are: an estimated half-life of 5.8–8.1 days in humans; high selectivity for the GHRH receptor on pituitary somatotrophs (the GH-producing cells); tissue distribution effectively confined to the bloodstream via albumin binding; and clearance through the normal turnover and proteolysis of albumin-bound peptide rather than through liver cytochrome enzymes such as CYP3A4 (a major drug-metabolizing liver enzyme), meaning classic drug-metabolism interactions are minimal. ## Historical Context & Evolution CJC-1295 was developed in the early 2000s by the Canadian biotechnology company ConjuChem as a long-acting GHRH analog. Its original intended use was therapeutic: to provide a practical way to stimulate growth hormone in conditions where the pituitary is intact but GH signaling is inadequate, overcoming the impractically short duration of natural GHRH and earlier analogs such as sermorelin. The first published characterization identified CJC-1295 as an albumin-binding GHRH fragment with a dramatically extended half-life in rats, and subsequent work showed once-daily dosing could normalize growth in GHRH-knockout mice. Two human trials around 2006 then demonstrated sustained GH and IGF-1 elevation in healthy adults and confirmed that pulsatile GH release was preserved. A company-sponsored phase 2 trial in HIV-associated visceral fat accumulation was also initiated during this period. The reasons it came to be considered for health optimization follow directly from this biology: because GH and IGF-1 decline with age and are associated with lean mass, body composition, recovery, and sleep, a compound that durably raises both from a single weekly-or-so injection was attractive to the longevity and performance communities. When clinical development did not lead to approval, CJC-1295 migrated into the gray-market peptide space, frequently combined with a growth hormone secretagogue such as ipamorelin. The evolution of scientific opinion here is not settled. Early findings that the compound is pharmacologically effective at raising GH/IGF-1 remain valid and undisputed. What changed is the surrounding context: growing attention to long-term safety gaps, a lack of large or long-duration human trials, and heightened regulatory scrutiny — culminating in a 2024 FDA Pharmacy Compounding Advisory Committee review that raised immunogenicity and product-quality concerns. New evidence has accumulated on both the efficacy side (consistent short-term hormonal effects) and the caution side (regulatory and quality issues), and the current standing is best described as "pharmacologically real, clinically under-studied." ## Expected Benefits ### High 🟩 🟩 🟩 #### Sustained Elevation of Growth Hormone and IGF-1 This is the one benefit directly and repeatedly demonstrated for CJC-1295 in humans: a single subcutaneous injection produces a large, dose-dependent rise in GH and a slower, longer rise in IGF-1. The mechanism is continuous GHRH-receptor stimulation via the albumin-bound peptide. The evidence basis is two placebo-controlled human trials (Teichman et al., 2006; Ionescu & Frohman, 2006) plus supporting animal and proteomic data. The important nuance for this audience is that this is a biomarker effect — raising the hormones is proven, but that these hormonal changes translate into the downstream longevity or body-composition outcomes people seek is not established in trials. **Magnitude:** Single doses raised mean GH 2- to 10-fold for ≥6 days and IGF-1 roughly 1.5- to 3-fold for 9–11 days; with repeated dosing, IGF-1 stayed above baseline up to 28 days. ### Medium 🟩 🟩 #### Preserved Pulsatile Growth Hormone Secretion Unlike administering growth hormone itself, CJC-1295 raises GH by prompting the body's own pulsatile release, and human data show the natural rhythm of GH pulses is retained rather than flattened. This matters because pulsatility is thought to be important for many of GH's physiological effects and may be gentler on the feedback systems that regulate the axis. The evidence basis is a controlled overnight sampling study in healthy men (Ionescu & Frohman, 2006). For the longevity-oriented reader, this is a mechanistic advantage over exogenous GH, though it has not been shown to produce superior clinical outcomes. **Magnitude:** Trough (baseline) GH rose ~7.5-fold and mean GH ~46% while pulse frequency and amplitude were statistically unchanged. ### Low 🟩 #### Improved Body Composition (Lean Mass and Fat Loss) Because GH and IGF-1 promote lean tissue and lipolysis (fat breakdown), CJC-1295 is widely used with the goal of increasing lean mass and reducing fat, particularly visceral fat. The proposed mechanism is durable GH/IGF-1 elevation driving the same body-composition effects seen with GH therapy and with the related, approved GHRH analog tesamorelin. The evidence basis for CJC-1295 specifically is weak: no completed, published human trial demonstrates body-composition endpoints, and the one registered trial in HIV-associated visceral fat was terminated. This benefit is therefore an extrapolation from adjacent compounds, not a demonstrated CJC-1295 outcome. **Magnitude:** Not quantified in available studies. #### Enhanced Recovery, Sleep, and Tissue Repair GH secretion is tightly linked to slow-wave (deep) sleep and to tissue repair, so raising nightly GH output is proposed to improve sleep quality, recovery, and connective-tissue healing — outcomes valued by proactive, performance-minded users. The mechanism is plausible given GH/IGF-1 biology and the preserved pulsatility of secretion. The evidence basis specific to CJC-1295 is anecdotal and expert-commentary level (e.g., discussion by Attia and Huberman); no controlled trial has measured sleep or recovery endpoints for this peptide. It is included at Low because the mechanism is sound but direct data are absent. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Longevity and Healthspan Extension ⚠️ Conflicted The aspiration most relevant to this audience — that restoring youthful GH/IGF-1 signaling could slow aspects of aging — is the least supported. No human or animal study has tested CJC-1295 against longevity or healthspan endpoints, and the broader aging-biology literature is genuinely conflicted: some models associate higher GH/IGF-1 with vitality and lean mass, while others associate lower IGF-1 signaling with longer lifespan. The basis here is mechanistic and theoretical only, and the direction of the net effect on longevity is unknown. ## Benefit-Modifying Factors * **Baseline GH/IGF-1 status:** Individuals with an intact pituitary but age-related decline in GH output are the intended responders; those with pituitary damage or already-high IGF-1 have little headroom to benefit and more reason for caution. * **Age:** GH and IGF-1 fall progressively with age, so middle-aged and older adults at the upper end of the target range may show a larger relative rise from a given dose, though they may also carry more accumulated cancer risk from IGF-1 elevation. * **Body composition and adiposity:** Higher body fat blunts GH secretion at baseline, so individuals with more visceral fat may have a lower GH response to GHRH-receptor stimulation than lean individuals. * **Sex-based differences:** Estrogen strongly modulates the GH/IGF-1 axis and GH sensitivity differs between men and women; however, CJC-1295 human trials were conducted largely or entirely in men, so sex-specific response data for this peptide are lacking and any expectation of similar effects in women is an extrapolation. * **Pre-existing conditions:** Insulin resistance or type 2 diabetes may modify the metabolic response, since GH/IGF-1 elevation can worsen insulin sensitivity, potentially offsetting benefit in those individuals. * **Genetic factors:** Polymorphisms in the GH receptor (notably the GHR d3 exon-3 deletion, a common variant affecting GH-receptor signaling) can alter downstream IGF-1 generation and tissue responsiveness, so the same hormonal rise may yield different effects between individuals. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Product Quality, Contamination, and Immunogenicity Risk For this audience the most immediate and best-documented risk is not the molecule's pharmacology but the way it is supplied. CJC-1295 is not an FDA-approved drug; it circulates through compounding pharmacies and gray-market "research use only" vendors, where purity, sterility, correct sequence, and dose accuracy are not guaranteed. The mechanism of harm includes injection of contaminated or misdosed material and, per the FDA's 2024 Pharmacy Compounding Advisory Committee review, the potential for the peptide to aggregate in injectable formulations and trigger an immune response (immunogenicity). The evidence basis is regulatory review documents and the structure of the unregulated market itself. Severity ranges from local reactions to serious immune or infectious events. **Magnitude:** Not quantified in available studies; risk scales with product source, with unregulated vendors carrying substantially higher likelihood of impurity or misdosing than licensed compounders. #### Injection Site Reactions As a subcutaneous injectable used repeatedly, CJC-1295 commonly causes local reactions — redness, swelling, itching, pain, or transient lumps at the injection site. The mechanism is a mix of mechanical needle trauma, local peptide/vehicle irritation, and possible immune reactivity. The evidence basis includes the human trials (which reported local tolerability observations) and consistent user-reported experience. These are generally mild and self-limiting but can be recurrent with ongoing use. **Magnitude:** Commonly reported; typically mild and transient, resolving within hours to a few days. ### Medium 🟥 🟥 #### Fluid Retention, Edema, and Related Effects Raising GH/IGF-1 promotes sodium and water retention, which can cause swelling (edema), a feeling of puffiness, and in the class more broadly carpal-tunnel-type symptoms and joint aches. The mechanism is GH-driven renal sodium retention and fluid shifts. The evidence basis is the well-characterized GH/GHRH class effect plus expert commentary specifically flagging CJC-1295 as more prone to fluid retention than sermorelin or tesamorelin (Huberman). Effects are usually dose-related and reversible on stopping, with the magnitude for CJC-1295 specifically not measured but inferred to be dose-dependent from class data. **Magnitude:** Not quantified in available studies. #### Impaired Glucose Tolerance and Insulin Resistance Growth hormone is counter-regulatory to insulin, so sustained GH/IGF-1 elevation can raise blood sugar and reduce insulin sensitivity, a meaningful concern for a metabolically-focused audience. The mechanism is GH-induced reduction in peripheral glucose uptake and increased lipolysis. The evidence basis is the extensive GH/IGF-1 literature; direct glucose endpoints were not the focus of the small CJC-1295 trials, so no magnitude specific to this peptide has been measured. At-risk populations include those with prediabetes, type 2 diabetes, or metabolic syndrome. **Magnitude:** Not quantified in available studies. ### Low 🟥 #### Cardiovascular and Vasomotor Effects Reports associated with GHRH-analog dosing include flushing, transient increases in heart rate, and vasodilatory reactions, and CJC-1295's regulatory scrutiny has referenced such adverse events. The proposed mechanism involves peptide-related vasomotor effects and, over the long term, the theoretical cardiac consequences of sustained GH/IGF-1 excess (as seen in acromegaly, a disease of chronic GH overproduction). The evidence basis is limited adverse-event reporting and class analogy. Data are sparse and causality for serious cardiac events is not established. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Long-Term Cancer Risk from Elevated IGF-1 The most consequential theoretical risk is that chronically elevated IGF-1 could promote the growth of existing or nascent tumors, since IGF-1 is a potent driver of cell proliferation and is epidemiologically associated with several cancers at the high end of the normal range. No study has evaluated cancer outcomes with CJC-1295, and the concern rests entirely on mechanism and on IGF-1 epidemiology rather than on direct data. Because the underlying use is chronic and the latency of cancer is long, this risk is both plausible and effectively unstudied, which is precisely why it is treated as speculative rather than dismissed. ## Risk-Modifying Factors * **Personal or family cancer history:** Because IGF-1 promotes cell proliferation, a personal history of cancer or high familial risk is the single most important factor amplifying the theoretical downside; those individuals face a less favorable risk profile. * **Baseline IGF-1 and glucose markers:** Individuals already at the high end of IGF-1, or with elevated fasting glucose/HbA1c (glycated hemoglobin, a measure of average blood sugar over the prior ~3 months), have less safety margin, as further elevation pushes them toward ranges associated with metabolic and proliferative risk. * **Pre-existing conditions:** Diabetes or impaired glucose tolerance heightens the metabolic risk; active malignancy is a reason to avoid the compound entirely; sleep apnea and heart disease may be aggravated by GH-related fluid retention. * **Sex-based differences:** GH/IGF-1 dynamics and fluid-handling differ by sex, but CJC-1295 was studied mainly in men, so risk estimates in women are extrapolated and carry additional uncertainty. * **Age:** Older adults may face greater cumulative exposure risk from sustained IGF-1 elevation and are more likely to harbor undetected early neoplasia, while also being more sensitive to fluid retention and glucose effects. * **Genetic factors:** Variants that increase downstream IGF-1 generation (e.g., certain GH-receptor genotypes) could amplify both benefits and proliferative risks from a given dose. ## Key Interactions & Contraindications * **Growth hormone secretagogues (ipamorelin, GHRP-6, GHRP-2, MK-677/ibutamoren):** CJC-1295 is most often combined with these, which act on a separate receptor and produce additive-to-synergistic GH release. Severity: caution — the combination markedly amplifies GH/IGF-1 exposure and therefore all GH-related risks (fluid retention, glucose impairment, proliferative concern). Mitigation: conservative dosing and monitoring of IGF-1 if combined. * **Exogenous growth hormone or other GHRH analogs (sermorelin, tesamorelin):** Concurrent use is redundant and additive. Severity: caution to avoid — stacking multiple GH-axis agents compounds the risk of acromegaly-like effects with no clear added benefit. * **Insulin and antidiabetic drugs (metformin, sulfonylureas, GLP-1 agonists — GLP-1, glucagon-like peptide-1, is a gut hormone that boosts insulin release):** GH elevation opposes insulin action and can raise blood glucose. Severity: monitor — may reduce the effectiveness of glucose-lowering therapy and worsen control. Mitigation: monitor glucose/HbA1c and adjust diabetic therapy under medical supervision. * **Corticosteroids (prednisone, dexamethasone):** Glucocorticoids blunt GH secretion and independently raise glucose. Severity: caution — may reduce CJC-1295's hormonal effect while compounding hyperglycemia risk. * **Thyroid hormone:** Thyroid status modulates the GH/IGF-1 axis; untreated hypothyroidism blunts the GH response. Severity: monitor — optimize thyroid status for expected response. * **Supplements affecting the GH axis or blood sugar (high-dose arginine, glutamine, GABA (gamma-aminobutyric acid, a calming brain chemical taken as a supplement); berberine, chromium):** Arginine and related amino acids can independently stimulate GH and may be additive; glucose-lowering supplements interact with GH's counter-regulatory effect. Severity: monitor — generally minor but relevant when stacking. * **Over-the-counter medications (NSAIDs such as ibuprofen/naproxen; oral decongestants such as pseudoephedrine):** GH-driven sodium and fluid retention can be compounded by NSAIDs, which themselves promote fluid retention, and sympathomimetic decongestants may add to any vasomotor/heart-rate effects. Severity: monitor — clinically minor for most users but worth spacing or avoiding during periods of noticeable edema. No clinically significant pharmacokinetic OTC interaction is documented for CJC-1295. * **Populations who should avoid CJC-1295:** individuals with active or recent cancer or high cancer risk; people with active proliferative diabetic retinopathy; pregnant or breastfeeding individuals; those with acromegaly or pituitary tumors; and anyone unable to obtain the product from a quality-assured source. Populations to avoid include specific thresholds where applicable: active malignancy (any current diagnosis or treatment within remission surveillance), uncontrolled diabetes (e.g., HbA1c >8%), and severe untreated sleep apnea. ## Risk Mitigation Strategies * **Source only from a licensed compounding pharmacy with a prescription:** the single highest-impact action, mitigating the High-rated product-quality, contamination, and immunogenicity risk by replacing "research use only" gray-market material with a quality-controlled, sterility-tested product. * **Baseline and periodic cancer and metabolic screening:** obtain age-appropriate cancer screening and a baseline before starting, then monitor to mitigate the speculative IGF-1-driven cancer risk and the metabolic risk; avoid entirely with any active malignancy. * **Monitor IGF-1 and keep it within the age-appropriate reference range:** check IGF-1 at baseline and every 3–6 months and reduce or stop dosing if IGF-1 rises above the upper end of the age-adjusted range, mitigating both the proliferative and acromegaly-like risks of over-elevation. * **Track fasting glucose and HbA1c:** measure at baseline and every 3–6 months to mitigate the risk of impaired glucose tolerance; discontinue or reduce dose if glucose control deteriorates. * **Use the lowest effective dose and rotate injection sites:** conservative dosing (e.g., starting at the low end of used ranges) mitigates fluid retention and metabolic effects, while rotating subcutaneous injection sites mitigates recurrent injection-site reactions. * **Avoid stacking multiple GH-axis agents without oversight:** limiting or carefully supervising combinations with secretagogues or GH mitigates the compounded risk of GH/IGF-1 excess and acromegaly-like effects. ## Therapeutic Protocol * **Standard practitioner approach:** In clinical/longevity practice, CJC-1295 with DAC is typically dosed once or twice weekly by subcutaneous injection, exploiting its 6–8 day half-life, with dosing often titrated to keep IGF-1 within an age-appropriate range rather than to a fixed target. Because it is not an approved product, "standard" protocols derive from prescriber practice and gray-market convention rather than from established guidelines. * **Competing approaches — with-DAC vs. no-DAC:** Two distinct strategies exist and are frequently conflated. The long-acting with-DAC form (true CJC-1295) gives a steady multi-day "bleed" of GH. A separate short-acting no-DAC form (often labeled Modified GRF 1-29) is dosed several times daily to more closely mimic natural pulsatile release. Neither is framed here as the default; the with-DAC form favors convenience and steady elevation, the no-DAC form favors physiological pulsatility. * **Combination vs. monotherapy:** Many practitioners pair CJC-1295 with a secretagogue such as ipamorelin to amplify pulsatile GH release; others use it alone. The CJC-1295 + ipamorelin pairing was popularized within functional and anti-aging peptide practice — notably by clinics affiliated with the American Academy of Anti-Aging Medicine (A4M) and by peptide-focused telehealth providers — rather than by a single named originator; the no-DAC (Modified GRF 1-29) approach traces to the pulsatility rationale discussed by endocrinology researchers such as Lawrence Frohman. This conflict of interest should be noted: A4M and the peptide-prescribing clinics that endorse these protocols derive direct revenue from the sale and administration of the peptides they recommend, so their advocacy is not disinterested. * **Best time of day:** Injection is commonly timed for the evening/before bed to align the induced GH rise with the natural nocturnal GH surge and slow-wave sleep, and dosing on an empty stomach (away from food, particularly high-carbohydrate meals) is advised because elevated glucose/insulin can blunt GH release. * **Half-life and dosing frequency:** Because the with-DAC form has a ~6–8 day half-life, weekly (or twice-weekly) single dosing maintains elevated IGF-1; the no-DAC form's very short half-life necessitates split, multiple-daily dosing to sustain effect. * **Genetic considerations:** GH-receptor variants (e.g., the exon-3 deletion) may influence downstream IGF-1 generation and thus the dose needed to reach a target IGF-1, supporting a titrate-to-IGF-1 rather than fixed-dose strategy. * **Sex-based considerations:** Since human data derive mainly from men, dosing in women is extrapolated; estrogen's modulation of the GH axis means response may differ, reinforcing individualized titration. * **Age considerations:** Older adults at the upper end of the target range may reach target IGF-1 at lower doses and warrant more conservative titration given greater cumulative-exposure concerns. * **Baseline biomarkers:** Baseline IGF-1 (and glucose markers) should anchor the starting dose and titration, as individuals already high in IGF-1 have little room to dose upward safely. * **Pre-existing conditions:** Metabolic disease, sleep apnea, or any cancer history materially change or contraindicate the protocol and must be factored into whether and how the compound is used. ## Discontinuation & Cycling * **Lifelong vs. short-term:** CJC-1295 is not established as a lifelong therapy; because long-term safety is unstudied, use is generally framed as time-limited courses rather than indefinite continuation, and there is no evidence-based endpoint defining an appropriate total duration. * **Withdrawal effects:** No physical withdrawal syndrome is described. On stopping, GH and IGF-1 return toward baseline over roughly one to several weeks (tracking the drug's clearance), and any gains attributed to elevated GH/IGF-1 are expected to regress rather than cause a rebound crash. * **Tapering:** Formal tapering is not required pharmacologically given the gradual decline dictated by the long half-life; the levels self-taper as albumin-bound peptide is cleared. * **Cycling:** Cycling (e.g., defined on/off periods) is commonly practiced in the peptide community with the stated aims of limiting cumulative IGF-1 exposure and preserving pituitary responsiveness, but no controlled data demonstrate that cycling maintains efficacy or reduces harm; the rationale is precautionary rather than evidence-based. * **Post-use monitoring:** After discontinuation, rechecking IGF-1 to confirm return toward the age-appropriate range is a reasonable practice, especially in anyone who ran high IGF-1 during use. ## Sourcing and Quality * **Regulatory status and source:** CJC-1295 is not FDA-approved; legitimate access is via a prescription filled by a licensed compounding pharmacy, whereas "research use only" websites are not quality-assured. Source is the dominant determinant of safety for this compound. * **What to look for:** Prefer material accompanied by a certificate of analysis documenting identity, purity (e.g., HPLC purity — measured by high-performance liquid chromatography, a lab method that separates and quantifies a sample's components — typically ≥98%), and low endotoxin/sterility for injectables; verify the peptide sequence and whether the product is the with-DAC or no-DAC form, since these are different compounds with different dosing. * **Compounding pharmacies:** Reputable, accredited compounding pharmacies (e.g., PCAB-accredited facilities) operating under a valid prescription are the most reliable source; note that the 2024 FDA advisory review created uncertainty about future compounding availability of CJC-1295. * **Purity and formulation pitfalls:** Injectable peptides can aggregate or degrade with poor manufacturing, temperature abuse, or improper reconstitution — the basis of the FDA's immunogenicity concern; lyophilized (freeze-dried) product should be reconstituted with appropriate sterile diluent and refrigerated, and mislabeling of no-DAC product as CJC-1295 is common in the gray market. * **Third-party testing:** Because dose accuracy and contamination are real risks, independent third-party analytical testing of a given batch is valuable where obtainable, and its absence should lower confidence in a product. ## Practical Considerations * **Time to effect:** Hormonal effects (rising IGF-1) begin within days of the first dose and plateau over roughly 4–6 weeks of regular dosing as steady state is reached; any perceived downstream benefits such as sleep or body-composition changes, if they occur, are reported over weeks to months and are not well characterized. * **Common pitfalls:** Confusing the with-DAC and no-DAC forms and therefore mis-dosing; sourcing from unverified vendors; over-dosing in pursuit of faster results (raising IGF-1 into risk ranges); dosing right after high-carbohydrate meals (blunting GH release); and neglecting IGF-1 and glucose monitoring. * **Regulatory status:** In the United States CJC-1295 is unapproved, has been subject to shifting compounding eligibility, and was reviewed by the FDA Pharmacy Compounding Advisory Committee in 2024; it is also a prohibited substance in competitive sport under anti-doping rules. * **Cost and accessibility:** Access is inconsistent and depends on prescriber willingness and compounding-pharmacy availability, both of which have been affected by regulatory changes; gray-market products are cheaper but carry the quality risks described above. ## Interaction with Foundational Habits * **Sleep:** Direct and potentially bidirectional. GH is naturally released during slow-wave sleep, so evening dosing is intended to reinforce the nocturnal GH surge and may improve perceived sleep depth; conversely, fluid retention or discomfort could disrupt sleep in some users. Practical consideration: dose in the evening and monitor subjective sleep quality. * **Nutrition:** Direct and blunting when mistimed. Elevated glucose and insulin suppress GH release, so dosing on an empty stomach and away from high-carbohydrate meals preserves the GH response; because CJC-1295 can nudge glucose upward, a lower-glycemic dietary pattern is a sensible pairing. Practical consideration: separate injections from meals, especially carbohydrate-heavy ones. * **Exercise:** Potentiating and complementary. Resistance and high-intensity exercise are themselves potent natural GH stimuli, so combining training with CJC-1295 is synergistic for the lean-mass and recovery goals users pursue; there is no evidence it blunts training adaptation. Practical consideration: no specific timing requirement relative to workouts, though some prefer post-exercise or bedtime dosing. * **Stress management:** Indirect. Chronic stress and elevated cortisol suppress the GH axis and worsen glucose handling, potentially opposing both the desired GH effect and metabolic safety; effective stress management supports the axis CJC-1295 targets. Practical consideration: address chronic stress and sleep as prerequisites rather than relying on the peptide to override them. ## Monitoring Protocol & Defining Success Before starting, baseline testing establishes whether the GH/IGF-1 axis has room to be safely raised and screens for the metabolic and proliferative conditions that would make use inadvisable. Ongoing monitoring then tracks both efficacy (IGF-1 in the intended range) and safety (glucose, and clinical signs of GH excess), with checks recommended at baseline, at roughly 6–8 weeks after starting or changing dose, and then every 3–6 months. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | IGF-1 | Upper-mid of the age- and sex-adjusted reference range; avoid exceeding the upper limit | Primary efficacy and safety marker; reflects GH stimulation | Interpret against age/sex norms; a single non-fasting draw is acceptable but keep timing consistent between draws | | Fasting glucose | 70–90 mg/dL | GH opposes insulin and can raise glucose | Requires 8–12 h fast; pair with insulin/HbA1c; conventional "normal" extends higher, to <100 mg/dL | | HbA1c | <5.4% | Detects worsening glucose control over ~3 months | No fasting needed; complements fasting glucose; conventional threshold for prediabetes is higher, at 5.7% | | Fasting insulin | 2–5 µIU/mL | Early signal of GH-driven insulin resistance | Draw fasting alongside glucose; enables HOMA-IR (Homeostatic Model Assessment of Insulin Resistance, a simple index of insulin resistance calculated from fasting glucose and insulin) estimation; conventional labs flag only much higher values | | IGFBP-3 | Age-adjusted mid-range | Binding protein for IGF-1; helps interpret GH-axis activity | Best paired with IGF-1; optional but adds context | Qualitative markers complement the labs and are often what users notice first: * Sleep quality and depth (particularly whether deep sleep feels improved or disrupted) * Energy levels and daytime vitality * Recovery from exercise and soft-tissue soreness * Body composition changes (subjective lean/fat shifts) * Any swelling, puffiness, joint aching, or tingling in the hands (early signs of fluid retention to act on) ## Emerging Research * **Only registered clinical trial (terminated):** [NCT00267527](https://clinicaltrials.gov/study/NCT00267527) — a ConjuChem-sponsored Phase 2 study of CJC-1295 in HIV patients with visceral obesity (planned enrollment ~120). Its terminated status is itself informative: the single company-run efficacy trial in a body-composition indication did not complete, underscoring how thin the completed clinical evidence base remains for outcomes beyond hormone levels. * **Foundational human pharmacology (efficacy direction):** The core human data remain the two 2006 trials — [Teichman et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16352683/) establishing dose-dependent multi-day GH/IGF-1 elevation, and [Ionescu & Frohman, 2006](https://pubmed.ncbi.nlm.nih.gov/17018654/) showing preserved pulsatility. Future work replicating these in older adults and women would strengthen the case; none is currently registered. * **Biomarker and mechanism work (mixed direction):** [Sackmann-Sala et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19386527/) identified serum protein changes after CJC-1295, illustrating the kind of mechanistic research that could either better characterize benefit or surface off-target effects; expanding this into long-term IGF-1/cancer-surveillance studies would directly address the field's biggest open question. * **Regulatory and safety evaluation (caution direction):** The 2024 FDA Pharmacy Compounding Advisory Committee review of CJC-1295 raised immunogenicity and product-quality concerns; ongoing regulatory and analytical scrutiny of compounded peptide quality is the most active "research" front and could weaken the practical case for use if quality cannot be assured. * **Key unanswered questions:** The areas most likely to change current understanding are long-term cancer risk from sustained IGF-1 elevation, hard clinical outcomes (body composition, function, healthspan) rather than hormone surrogates, and head-to-head comparison with approved GHRH analogs such as tesamorelin — none of which has been adequately studied for CJC-1295. ## Conclusion CJC-1295 is a lab-made, long-acting copy of the natural signal that tells the body to release its own growth hormone. Its one clearly proven effect in people is exactly that: a single injection reliably raises growth hormone and its downstream messenger for many days, while keeping the body's natural release rhythm. Beyond that biomarker effect, the evidence thins quickly. The hoped-for goals that draw health- and longevity-minded users — better body composition, recovery, sleep, and slower aging — rest mostly on how growth hormone behaves in general, not on studies of this peptide, and the one company trial aimed at a real-world outcome did not finish. Against modest, mostly indirect potential benefits sit real and partly unmeasured concerns: fluid retention, higher blood sugar, and a plausible but untested worry that years of raised growth-signaling could feed cancer. Compounding this, the product itself is not an approved medicine, so quality, purity, and correct dosing vary widely by source. The overall evidence base is small, short-term, largely industry-generated, and silent on long-term safety, and much of the enthusiasm comes from clinics and sellers who profit directly from prescribing it. What is known is that it works hormonally; what is not known is whether that translates into the durable health gains people seek, or at what long-term cost. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**